Depression remains the leading cause of disability worldwide, affecting almost 300 million people, half of whom can’t find lasting relief from drugs or therapy. But a new experimental treatment using a fast-acting approach with targeted magnetic stimulation, called SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), has achieved significant success in trials. Correspondent Lee Cowan reports.
